Molecular Evaluation of the Impact of Polymorphic Variants in Apoptotic (Bcl-2/Bax) and Proinflammatory Cytokine (TNF-α/IL-8) Genes on the Susceptibility and Progression of Myeloproliferative Neoplasms: A Case-Control Biomarker Study
The regulation of apoptosis (the programmed cell death) is dependent on the crucial involvement of BCL2 and BAX. The Bax-248G>A and Bcl-2-938 C>A polymorphic variations in the promoter sequences of the Bax and Bcl-2 gene have been recently associated with low Bax expression, progression to adv...
Saved in:
| Published in | Current issues in molecular biology Vol. 45; no. 5; pp. 3933 - 3952 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
MDPI
02.05.2023
MDPI AG |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1467-3045 1467-3037 1467-3045 |
| DOI | 10.3390/cimb45050251 |
Cover
| Abstract | The regulation of apoptosis (the programmed cell death) is dependent on the crucial involvement of BCL2 and BAX. The Bax-248G>A and Bcl-2-938 C>A polymorphic variations in the promoter sequences of the Bax and Bcl-2 gene have been recently associated with low Bax expression, progression to advanced stages, treatment resistance, and shortened overall survival rate in some hematological malignancies, including chronic myeloid leukemia (CML) and other myeloproliferative neoplasms. Chronic inflammation has been linked to various stages of carcinogenesis wherein pro-inflammatory cytokines play diverse roles in influencing cancer microenvironment leading to cell invasion and cancer progression. Cytokines such as TNF-α and IL-8 have been implicated in cancer growth in both solid and hematological malignancies with studies showing their elevated levels in patients. Genomic approaches have in recent years provided significant knowledge with the regard to the association of certain SNPs (single nucleotide polymerphisms) either in a gene or its promoter that can influence its expression, with the risk and susceptibility to human diseases including cancer. This study has investigated the consequences of promoter SNPs in apoptosis genes Bax-248G>A (rs4645878)/Bcl-2-938C>A (rs2279115) and pro-inflammatory cytokines TNF-α rs1800629 G>A/IL-8 rs4073 T>A on the risk and susceptibility towards hematological cancers. The study design has 235 individuals both male and female enrolled as subjects that had 113 cases of MPDs (myeloproliferative disorders) and 122 healthy individuals as controls. The genotyping studies were conducted through ARMS PCR (amplification-refractory mutation system PCR). The Bcl-2-938 C>A polymorphism showed up in 22% of patients in the study, while it was observed in only 10% of normal controls. This difference in genotype and allele frequency between the two groups was significant (p = 0.025). Similarly, the Bax-248G>A polymorphism was detected in 6.48% of the patients and 4.54% of the normal controls, with a significant difference in genotype and allele frequency between the groups (p = 0.048). The results suggest that the Bcl-2-938 C>A variant is linked to an elevated risk of MPDs in the codominant, dominant, and recessive inheritance models. Moreover, the study indicated allele A as risk allele which can significantly increase the risk of MPDs unlike the C allele. In case of Bax gene covariants, these were associated with an increased risk of MPDs in the codominant inheritance model and dominant inheritance model. It was found that the allele A significantly enhanced the risk of MPDs unlike the G allele. The frequencies of IL-8 rs4073 T>A in patients was found to be TT (16.39%), AT (36.88%) and AA (46.72%), compared to controls who were more likely to have frequencies of TT (39.34%), AT (37.70%) and AA (22.95%) as such, respectively. There was a notable overrepresentation of the AA genotype and GG homozygotes among patients compared to controls in TNF-α polymorphic variants, with 6.55% of patients having the AA genotype and 84% of patients being GG homozygotes, compared to 1.63% and 69%, respectively in controls. The data from the current study provide partial but important evidence that polymorphisms in apoptotic genes Bcl-2-938C>A and Bax-248G>A and pro-inflammatory cytokines IL-8 rs4073 T>A and TNF-α G>A may help predict the clinical outcomes of patients and determine the significance of such polymorphic variations in the risk of myeloproliferative diseases and their role as prognostic markers in disease management using a case-control study approach. |
|---|---|
| AbstractList | The regulation of apoptosis (the programmed cell death) is dependent on the crucial involvement of BCL2 and BAX. The
and
polymorphic variations in the promoter sequences of the
and
gene have been recently associated with low
expression, progression to advanced stages, treatment resistance, and shortened overall survival rate in some hematological malignancies, including chronic myeloid leukemia (CML) and other myeloproliferative neoplasms. Chronic inflammation has been linked to various stages of carcinogenesis wherein pro-inflammatory cytokines play diverse roles in influencing cancer microenvironment leading to cell invasion and cancer progression. Cytokines such as TNF-α and IL-8 have been implicated in cancer growth in both solid and hematological malignancies with studies showing their elevated levels in patients. Genomic approaches have in recent years provided significant knowledge with the regard to the association of certain SNPs (single nucleotide polymerphisms) either in a gene or its promoter that can influence its expression, with the risk and susceptibility to human diseases including cancer. This study has investigated the consequences of promoter SNPs in apoptosis genes
)/
and pro-inflammatory cytokines
on the risk and susceptibility towards hematological cancers. The study design has 235 individuals both male and female enrolled as subjects that had 113 cases of MPDs (myeloproliferative disorders) and 122 healthy individuals as controls. The genotyping studies were conducted through ARMS PCR (amplification-refractory mutation system PCR). The
polymorphism showed up in 22% of patients in the study, while it was observed in only 10% of normal controls. This difference in genotype and allele frequency between the two groups was significant (
= 0.025). Similarly, the
polymorphism was detected in 6.48% of the patients and 4.54% of the normal controls, with a significant difference in genotype and allele frequency between the groups (
= 0.048). The results suggest that the
variant is linked to an elevated risk of MPDs in the codominant, dominant, and recessive inheritance models. Moreover, the study indicated allele A as risk allele which can significantly increase the risk of MPDs unlike the C allele. In case of
gene covariants, these were associated with an increased risk of MPDs in the codominant inheritance model and dominant inheritance model. It was found that the allele A significantly enhanced the risk of MPDs unlike the G allele. The frequencies of
in patients was found to be TT (16.39%), AT (36.88%) and AA (46.72%), compared to controls who were more likely to have frequencies of TT (39.34%), AT (37.70%) and AA (22.95%) as such, respectively. There was a notable overrepresentation of the AA genotype and GG homozygotes among patients compared to controls in
polymorphic variants, with 6.55% of patients having the AA genotype and 84% of patients being GG homozygotes, compared to 1.63% and 69%, respectively in controls. The data from the current study provide partial but important evidence that polymorphisms in apoptotic genes
and
and pro-inflammatory cytokines
and
may help predict the clinical outcomes of patients and determine the significance of such polymorphic variations in the risk of myeloproliferative diseases and their role as prognostic markers in disease management using a case-control study approach. The regulation of apoptosis (the programmed cell death) is dependent on the crucial involvement of BCL2 and BAX. The Bax-248G>A and Bcl-2-938 C>A polymorphic variations in the promoter sequences of the Bax and Bcl-2 gene have been recently associated with low Bax expression, progression to advanced stages, treatment resistance, and shortened overall survival rate in some hematological malignancies, including chronic myeloid leukemia (CML) and other myeloproliferative neoplasms. Chronic inflammation has been linked to various stages of carcinogenesis wherein pro-inflammatory cytokines play diverse roles in influencing cancer microenvironment leading to cell invasion and cancer progression. Cytokines such as TNF-α and IL-8 have been implicated in cancer growth in both solid and hematological malignancies with studies showing their elevated levels in patients. Genomic approaches have in recent years provided significant knowledge with the regard to the association of certain SNPs (single nucleotide polymerphisms) either in a gene or its promoter that can influence its expression, with the risk and susceptibility to human diseases including cancer. This study has investigated the consequences of promoter SNPs in apoptosis genes Bax-248G>A (rs4645878)/Bcl-2-938C>A (rs2279115) and pro-inflammatory cytokines TNF-α rs1800629 G>A/IL-8 rs4073 T>A on the risk and susceptibility towards hematological cancers. The study design has 235 individuals both male and female enrolled as subjects that had 113 cases of MPDs (myeloproliferative disorders) and 122 healthy individuals as controls. The genotyping studies were conducted through ARMS PCR (amplification-refractory mutation system PCR). The Bcl-2-938 C>A polymorphism showed up in 22% of patients in the study, while it was observed in only 10% of normal controls. This difference in genotype and allele frequency between the two groups was significant (p = 0.025). Similarly, the Bax-248G>A polymorphism was detected in 6.48% of the patients and 4.54% of the normal controls, with a significant difference in genotype and allele frequency between the groups (p = 0.048). The results suggest that the Bcl-2-938 C>A variant is linked to an elevated risk of MPDs in the codominant, dominant, and recessive inheritance models. Moreover, the study indicated allele A as risk allele which can significantly increase the risk of MPDs unlike the C allele. In case of Bax gene covariants, these were associated with an increased risk of MPDs in the codominant inheritance model and dominant inheritance model. It was found that the allele A significantly enhanced the risk of MPDs unlike the G allele. The frequencies of IL-8 rs4073 T>A in patients was found to be TT (16.39%), AT (36.88%) and AA (46.72%), compared to controls who were more likely to have frequencies of TT (39.34%), AT (37.70%) and AA (22.95%) as such, respectively. There was a notable overrepresentation of the AA genotype and GG homozygotes among patients compared to controls in TNF-α polymorphic variants, with 6.55% of patients having the AA genotype and 84% of patients being GG homozygotes, compared to 1.63% and 69%, respectively in controls. The data from the current study provide partial but important evidence that polymorphisms in apoptotic genes Bcl-2-938C>A and Bax-248G>A and pro-inflammatory cytokines IL-8 rs4073 T>A and TNF-α G>A may help predict the clinical outcomes of patients and determine the significance of such polymorphic variations in the risk of myeloproliferative diseases and their role as prognostic markers in disease management using a case-control study approach.The regulation of apoptosis (the programmed cell death) is dependent on the crucial involvement of BCL2 and BAX. The Bax-248G>A and Bcl-2-938 C>A polymorphic variations in the promoter sequences of the Bax and Bcl-2 gene have been recently associated with low Bax expression, progression to advanced stages, treatment resistance, and shortened overall survival rate in some hematological malignancies, including chronic myeloid leukemia (CML) and other myeloproliferative neoplasms. Chronic inflammation has been linked to various stages of carcinogenesis wherein pro-inflammatory cytokines play diverse roles in influencing cancer microenvironment leading to cell invasion and cancer progression. Cytokines such as TNF-α and IL-8 have been implicated in cancer growth in both solid and hematological malignancies with studies showing their elevated levels in patients. Genomic approaches have in recent years provided significant knowledge with the regard to the association of certain SNPs (single nucleotide polymerphisms) either in a gene or its promoter that can influence its expression, with the risk and susceptibility to human diseases including cancer. This study has investigated the consequences of promoter SNPs in apoptosis genes Bax-248G>A (rs4645878)/Bcl-2-938C>A (rs2279115) and pro-inflammatory cytokines TNF-α rs1800629 G>A/IL-8 rs4073 T>A on the risk and susceptibility towards hematological cancers. The study design has 235 individuals both male and female enrolled as subjects that had 113 cases of MPDs (myeloproliferative disorders) and 122 healthy individuals as controls. The genotyping studies were conducted through ARMS PCR (amplification-refractory mutation system PCR). The Bcl-2-938 C>A polymorphism showed up in 22% of patients in the study, while it was observed in only 10% of normal controls. This difference in genotype and allele frequency between the two groups was significant (p = 0.025). Similarly, the Bax-248G>A polymorphism was detected in 6.48% of the patients and 4.54% of the normal controls, with a significant difference in genotype and allele frequency between the groups (p = 0.048). The results suggest that the Bcl-2-938 C>A variant is linked to an elevated risk of MPDs in the codominant, dominant, and recessive inheritance models. Moreover, the study indicated allele A as risk allele which can significantly increase the risk of MPDs unlike the C allele. In case of Bax gene covariants, these were associated with an increased risk of MPDs in the codominant inheritance model and dominant inheritance model. It was found that the allele A significantly enhanced the risk of MPDs unlike the G allele. The frequencies of IL-8 rs4073 T>A in patients was found to be TT (16.39%), AT (36.88%) and AA (46.72%), compared to controls who were more likely to have frequencies of TT (39.34%), AT (37.70%) and AA (22.95%) as such, respectively. There was a notable overrepresentation of the AA genotype and GG homozygotes among patients compared to controls in TNF-α polymorphic variants, with 6.55% of patients having the AA genotype and 84% of patients being GG homozygotes, compared to 1.63% and 69%, respectively in controls. The data from the current study provide partial but important evidence that polymorphisms in apoptotic genes Bcl-2-938C>A and Bax-248G>A and pro-inflammatory cytokines IL-8 rs4073 T>A and TNF-α G>A may help predict the clinical outcomes of patients and determine the significance of such polymorphic variations in the risk of myeloproliferative diseases and their role as prognostic markers in disease management using a case-control study approach. The regulation of apoptosis (the programmed cell death) is dependent on the crucial involvement of BCL2 and BAX. The Bax-248G>A and Bcl-2-938 C>A polymorphic variations in the promoter sequences of the Bax and Bcl-2 gene have been recently associated with low Bax expression, progression to advanced stages, treatment resistance, and shortened overall survival rate in some hematological malignancies, including chronic myeloid leukemia (CML) and other myeloproliferative neoplasms. Chronic inflammation has been linked to various stages of carcinogenesis wherein pro-inflammatory cytokines play diverse roles in influencing cancer microenvironment leading to cell invasion and cancer progression. Cytokines such as TNF-α and IL-8 have been implicated in cancer growth in both solid and hematological malignancies with studies showing their elevated levels in patients. Genomic approaches have in recent years provided significant knowledge with the regard to the association of certain SNPs (single nucleotide polymerphisms) either in a gene or its promoter that can influence its expression, with the risk and susceptibility to human diseases including cancer. This study has investigated the consequences of promoter SNPs in apoptosis genes Bax-248G>A (rs4645878)/Bcl-2-938C>A (rs2279115) and pro-inflammatory cytokines TNF-α rs1800629 G>A/IL-8 rs4073 T>A on the risk and susceptibility towards hematological cancers. The study design has 235 individuals both male and female enrolled as subjects that had 113 cases of MPDs (myeloproliferative disorders) and 122 healthy individuals as controls. The genotyping studies were conducted through ARMS PCR (amplification-refractory mutation system PCR). The Bcl-2-938 C>A polymorphism showed up in 22% of patients in the study, while it was observed in only 10% of normal controls. This difference in genotype and allele frequency between the two groups was significant (p = 0.025). Similarly, the Bax-248G>A polymorphism was detected in 6.48% of the patients and 4.54% of the normal controls, with a significant difference in genotype and allele frequency between the groups (p = 0.048). The results suggest that the Bcl-2-938 C>A variant is linked to an elevated risk of MPDs in the codominant, dominant, and recessive inheritance models. Moreover, the study indicated allele A as risk allele which can significantly increase the risk of MPDs unlike the C allele. In case of Bax gene covariants, these were associated with an increased risk of MPDs in the codominant inheritance model and dominant inheritance model. It was found that the allele A significantly enhanced the risk of MPDs unlike the G allele. The frequencies of IL-8 rs4073 T>A in patients was found to be TT (16.39%), AT (36.88%) and AA (46.72%), compared to controls who were more likely to have frequencies of TT (39.34%), AT (37.70%) and AA (22.95%) as such, respectively. There was a notable overrepresentation of the AA genotype and GG homozygotes among patients compared to controls in TNF-α polymorphic variants, with 6.55% of patients having the AA genotype and 84% of patients being GG homozygotes, compared to 1.63% and 69%, respectively in controls. The data from the current study provide partial but important evidence that polymorphisms in apoptotic genes Bcl-2-938C>A and Bax-248G>A and pro-inflammatory cytokines IL-8 rs4073 T>A and TNF-α G>A may help predict the clinical outcomes of patients and determine the significance of such polymorphic variations in the risk of myeloproliferative diseases and their role as prognostic markers in disease management using a case-control study approach. The regulation of apoptosis (the programmed cell death) is dependent on the crucial involvement of BCL2 and BAX. The Bax-248G>A and Bcl-2-938 C>A polymorphic variations in the promoter sequences of the Bax and Bcl-2 gene have been recently associated with low Bax expression, progression to advanced stages, treatment resistance, and shortened overall survival rate in some hematological malignancies, including chronic myeloid leukemia (CML) and other myeloproliferative neoplasms. Chronic inflammation has been linked to various stages of carcinogenesis wherein pro-inflammatory cytokines play diverse roles in influencing cancer microenvironment leading to cell invasion and cancer progression. Cytokines such as TNF-α and IL-8 have been implicated in cancer growth in both solid and hematological malignancies with studies showing their elevated levels in patients. Genomic approaches have in recent years provided significant knowledge with the regard to the association of certain SNPs (single nucleotide polymerphisms) either in a gene or its promoter that can influence its expression, with the risk and susceptibility to human diseases including cancer. This study has investigated the consequences of promoter SNPs in apoptosis genes Bax-248G>A (rs4645878 )/ Bcl-2-938C>A (rs2279115) and pro-inflammatory cytokines TNF-α rs1800629 G>A/IL-8 rs4073 T>A on the risk and susceptibility towards hematological cancers. The study design has 235 individuals both male and female enrolled as subjects that had 113 cases of MPDs (myeloproliferative disorders) and 122 healthy individuals as controls. The genotyping studies were conducted through ARMS PCR (amplification-refractory mutation system PCR). The Bcl-2-938 C>A polymorphism showed up in 22% of patients in the study, while it was observed in only 10% of normal controls. This difference in genotype and allele frequency between the two groups was significant ( p = 0.025). Similarly, the Bax-248G>A polymorphism was detected in 6.48% of the patients and 4.54% of the normal controls, with a significant difference in genotype and allele frequency between the groups ( p = 0.048). The results suggest that the Bcl-2-938 C>A variant is linked to an elevated risk of MPDs in the codominant, dominant, and recessive inheritance models. Moreover, the study indicated allele A as risk allele which can significantly increase the risk of MPDs unlike the C allele. In case of Bax gene covariants, these were associated with an increased risk of MPDs in the codominant inheritance model and dominant inheritance model. It was found that the allele A significantly enhanced the risk of MPDs unlike the G allele. The frequencies of IL-8 rs4073 T>A in patients was found to be TT (16.39%), AT (36.88%) and AA (46.72%), compared to controls who were more likely to have frequencies of TT (39.34%), AT (37.70%) and AA (22.95%) as such, respectively. There was a notable overrepresentation of the AA genotype and GG homozygotes among patients compared to controls in TNF-α polymorphic variants, with 6.55% of patients having the AA genotype and 84% of patients being GG homozygotes, compared to 1.63% and 69%, respectively in controls. The data from the current study provide partial but important evidence that polymorphisms in apoptotic genes Bcl-2-938C>A and Bax-248G>A and pro-inflammatory cytokines IL-8 rs4073 T>A and TNF-α G>A may help predict the clinical outcomes of patients and determine the significance of such polymorphic variations in the risk of myeloproliferative diseases and their role as prognostic markers in disease management using a case-control study approach. |
| Author | Ullah, Mohammad Fahad Tayeb, Faris J. Asim, Orooba Moawadh, Mamdoh S. Mir, Rashid |
| AuthorAffiliation | 3 Community College, University of Tabuk, Tabuk 71491, Saudi Arabia 1 Department of Medical Laboratory Technology (FAMS), University of Tabuk, Tabuk 71491, Saudi Arabia 2 Division of Molecular Biology, Prince Fahd Chair for Biomedical Research, University of Tabuk, Tabuk 71491, Saudi Arabia |
| AuthorAffiliation_xml | – name: 1 Department of Medical Laboratory Technology (FAMS), University of Tabuk, Tabuk 71491, Saudi Arabia – name: 2 Division of Molecular Biology, Prince Fahd Chair for Biomedical Research, University of Tabuk, Tabuk 71491, Saudi Arabia – name: 3 Community College, University of Tabuk, Tabuk 71491, Saudi Arabia |
| Author_xml | – sequence: 1 givenname: Mamdoh S. surname: Moawadh fullname: Moawadh, Mamdoh S. – sequence: 2 givenname: Rashid surname: Mir fullname: Mir, Rashid – sequence: 3 givenname: Faris J. orcidid: 0000-0002-8906-198X surname: Tayeb fullname: Tayeb, Faris J. – sequence: 4 givenname: Orooba orcidid: 0000-0003-0760-8759 surname: Asim fullname: Asim, Orooba – sequence: 5 givenname: Mohammad Fahad orcidid: 0000-0002-8059-5571 surname: Ullah fullname: Ullah, Mohammad Fahad |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37232720$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkstu1DAUhiNURC-wY428nEqE-pYbG9SO2jJSWyq1sI0c52TGrWMH26nIY_EiPAhPgaedohaxsn38-_uPj_7dZMtYA0nyluAPjFX4QKq-4RnOMM3Ii2SH8LxIGebZ1pP9drLr_Q3GWVEW5FWyzQrKaEHxTvL73GqQoxYOHd8JPYqgrEG2Q2EFaNEPQob16dLqqbduWCmJvgmnhAkeKYMOBzsEG2J1diR1Sg-OxI99JEyLLp1VptOi70WwbkLzKdhbZQDNri9O0l8_DxZnabmPTsGAR9Fy7Xc1eglDUI3SKkyPmKUD7zddnU-g7eCsVh242OsdoAuwgxa-9x_RIZoLD-ncmhAl6EjZXrhbcOgqjO30OnnZCe3hzWbdS76eHF_PP6dnX04X88OzVPKMhLTgohS84qSjjEALLa_aLCcthoZXEncd523Jc0aqSoosz7ui7AAYhQ7yMssk20sWD9zWipt6cCo2MdVWqPq-YN2yFi6OTEPNG4pL3kKF85Z3TDRlSxkrSFORkvJmzfr0wBrGpodWQvyZ0M-gz2-MWtVLe1cTTEnBijwSZhuCs99H8KHuVZyy1sKAHX1NS4oxycqiitJ3T83-ujymJQrog0A6672DrpYq3CcmeisdTet1JOunkYyP3v_z6JH7X_kfoUvnYg |
| CitedBy_id | crossref_primary_10_3390_cimb47010014 crossref_primary_10_2174_0113892029272497240103052359 crossref_primary_10_1186_s12876_024_03564_6 crossref_primary_10_3390_life14080949 crossref_primary_10_18502_ijrm_v22i6_16796 crossref_primary_10_3390_ijms242216309 |
| Cites_doi | 10.1007/s00580-017-2600-6 10.1371/journal.pone.0085187 10.1016/j.molcel.2011.10.001 10.1002/jcla.22961 10.21873/anticanres.15870 10.1002/hed.25471 10.1016/j.leukres.2009.05.009 10.1155/2014/149185 10.1158/0008-5472.CAN-08-1565 10.1038/s41467-021-23097-w 10.1158/0008-5472.CAN-11-0156 10.1053/j.seminhematol.2004.02.011 10.1182/blood-2008-07-169110 10.1038/nrc883 10.1038/385637a0 10.1038/srep18411 10.1177/172460080902400402 10.3390/cancers12020524 10.1097/JTO.0b013e3181f8a20e 10.4149/neo_2012_061 10.1002/dc.21580 10.1007/s12079-019-00508-8 10.1038/s41598-019-51258-x 10.1002/(SICI)1096-9896(199812)186:4<378::AID-PATH203>3.0.CO;2-5 10.3322/caac.21492 10.1159/000342854 10.1016/j.pharmthera.2021.107943 10.3390/genes13071237 10.1038/35037710 10.1073/pnas.72.9.3666 10.3390/ijms21041177 10.3390/cancers13030529 10.1158/2159-8290.CD-17-1178 10.1182/blood.V82.8.2517.2517 10.1158/0008-5472.CAN-11-3123 10.1309/JQ2X3RV3L8F9TGYW 10.1038/s41416-019-0617-0 10.1002/9781444318531 10.1016/S0145-2126(97)00006-4 10.1093/jjco/hyn089 10.1158/1078-0432.CCR-06-3063 10.1093/carcin/bgm172 10.1016/j.exphem.2016.10.005 10.2337/db08-0178 10.1016/j.molcel.2009.10.011 10.1002/ijc.25904 10.3390/ijms222212516 10.1371/journal.pone.0060915 10.3171/2010.12.JNS10478 10.1177/2050312120965752 10.1200/JCO.1999.17.5.1364 10.1371/journal.pone.0077534 10.4103/aam.aam_56_18 10.1084/jem.20181892 10.1007/s12308-008-0003-y 10.1007/978-3-642-16483-5 10.1126/science.270.5233.96 10.4172/0974-8369.1000424 10.1186/1471-2407-13-452 10.1038/s41375-022-01736-5 10.1038/emboj.2011.307 10.1007/s00125-022-05654-0 10.3389/fimmu.2019.01818 10.1200/JCO.2005.02.192 10.1177/0300060520904863 10.1016/j.jamcollsurg.2003.08.008 10.1186/bcr3436 10.1002/cam4.2424 10.1186/1471-2350-12-48 10.3390/cells10010100 10.1016/0092-8674(93)90464-2 10.1006/jsre.2002.6473 10.1159/000514885 10.1016/j.juro.2009.03.081 10.3390/jpm12101607 10.1007/s13277-013-1299-5 10.1016/0165-4608(95)00341-X 10.1590/s0004-2803.202000000-16 10.1097/MD.0000000000011591 10.1158/1078-0432.CCR-06-2673 10.1007/s10038-005-0344-7 10.1080/13685538.2018.1470233 10.1007/s004280050034 |
| ContentType | Journal Article |
| Copyright | 2023 by the authors. 2023 |
| Copyright_xml | – notice: 2023 by the authors. 2023 |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.3390/cimb45050251 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1467-3045 |
| EndPage | 3952 |
| ExternalDocumentID | oai_doaj_org_article_4b2084de906d4f3ab8d23371b91824bc PMC10217376 37232720 10_3390_cimb45050251 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Deanship of Scientific Research, University of Tabuk, Saudi Arabia grantid: 1441-0121 |
| GroupedDBID | --- 36B 53G 5GY AAYXX AENEX AFZYC ALMA_UNASSIGNED_HOLDINGS CITATION DIK E3Z EMB F5P FRP GROUPED_DOAJ GX1 IAO IGS IHR INH ITC MODMG OK1 PGMZT RNS RPM TR2 NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c451t-74a8a4941f231eded49d561d0eb49c0ff44d8463199ca566f78fee32efe6855c3 |
| IEDL.DBID | DOA |
| ISSN | 1467-3045 1467-3037 |
| IngestDate | Wed Aug 27 01:27:39 EDT 2025 Thu Aug 21 18:37:49 EDT 2025 Thu Jul 10 23:46:19 EDT 2025 Mon Jul 21 05:48:34 EDT 2025 Tue Jul 01 01:56:28 EDT 2025 Thu Apr 24 23:07:48 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | proinflammatory cytokines ET—essential thrombocythemia MPDs apoptosis CML—chronic myeloid leukaemia PV—polycythemia vera single nucleotide polymorphisms gene promoter |
| Language | English |
| License | https://creativecommons.org/licenses/by/4.0 Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c451t-74a8a4941f231eded49d561d0eb49c0ff44d8463199ca566f78fee32efe6855c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Internship Trainee. |
| ORCID | 0000-0002-8906-198X 0000-0002-8059-5571 0000-0003-0760-8759 |
| OpenAccessLink | https://doaj.org/article/4b2084de906d4f3ab8d23371b91824bc |
| PMID | 37232720 |
| PQID | 2820015879 |
| PQPubID | 23479 |
| PageCount | 20 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_4b2084de906d4f3ab8d23371b91824bc pubmedcentral_primary_oai_pubmedcentral_nih_gov_10217376 proquest_miscellaneous_2820015879 pubmed_primary_37232720 crossref_citationtrail_10_3390_cimb45050251 crossref_primary_10_3390_cimb45050251 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-05-02 |
| PublicationDateYYYYMMDD | 2023-05-02 |
| PublicationDate_xml | – month: 05 year: 2023 text: 2023-05-02 day: 02 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Current issues in molecular biology |
| PublicationTitleAlternate | Curr Issues Mol Biol |
| PublicationYear | 2023 |
| Publisher | MDPI MDPI AG |
| Publisher_xml | – name: MDPI – name: MDPI AG |
| References | Strasser (ref_8) 2011; 30 Kuett (ref_38) 2015; 5 Hengartner (ref_9) 2000; 407 Porebska (ref_59) 2006; 20 ref_90 Handa (ref_10) 1997; 21 Bachmann (ref_16) 2011; 114 Yin (ref_66) 1997; 385 ref_14 Masago (ref_17) 2013; 84 Yigit (ref_63) 2012; 59 Amin (ref_33) 2020; 8 Mehta (ref_81) 2018; 8 Hirata (ref_13) 2009; 182 Anvari (ref_62) 2012; 9 Alkhiary (ref_87) 2018; 27 ref_19 Kim (ref_53) 2009; 113 Jeong (ref_60) 2008; 38 Torrealba (ref_68) 2021; 23 Zhu (ref_72) 2020; 48 Peng (ref_67) 1998; 186 Matheson (ref_43) 2006; 51 Sturm (ref_55) 1999; 17 Liu (ref_88) 2019; 33 ref_25 ref_22 Singh (ref_74) 2013; 15 Bukholm (ref_20) 2000; 436 Bray (ref_1) 2018; 68 Fernando (ref_76) 2011; 71 Place (ref_29) 2019; 216 Knudson (ref_65) 1995; 270 ref_27 Kumar (ref_31) 2019; 121 Kang (ref_57) 2007; 13 Tripon (ref_86) 2019; 8 Knoefel (ref_51) 2011; 6 Zhou (ref_35) 2017; 45 Li (ref_80) 2009; 69 Cory (ref_5) 2002; 2 Linjawi (ref_21) 2004; 198 Montfort (ref_34) 2019; 10 Carswell (ref_78) 1975; 72 Verma (ref_84) 2022; 14 ref_36 Sun (ref_58) 2018; 16 ref_77 Li (ref_82) 2012; 72 Autret (ref_3) 2009; 36 Dettmer (ref_30) 2022; 65 Ochi (ref_89) 2021; 12 Spivak (ref_49) 2004; 41 Moghimi (ref_75) 2020; 57 Wang (ref_71) 2022; 42 Pirocanac (ref_54) 2002; 106 Grunnet (ref_28) 2009; 58 Bonzheim (ref_50) 2008; 1 Feng (ref_70) 2018; 97 Abdalhabib (ref_73) 2022; 15 Chou (ref_18) 1996; 88 Bachmann (ref_52) 2011; 129 Bachmann (ref_11) 2007; 13 (ref_64) 2012; 40 Tobler (ref_39) 1993; 82 ref_47 Butt (ref_42) 2017; 10 ref_46 Starczynski (ref_24) 2005; 23 ref_44 Senapati (ref_45) 2023; 37 Lello (ref_41) 2019; 9 ref_85 ref_40 Miquel (ref_56) 2005; 123 Landskron (ref_32) 2014; 2014 ref_2 Singh (ref_26) 2019; 18 Liao (ref_83) 2019; 13 Moon (ref_15) 2010; 34 Alam (ref_69) 2019; 41 Tartaglia (ref_79) 1993; 74 Li (ref_23) 2014; 35 ref_48 Llambi (ref_7) 2011; 44 Bernhard (ref_37) 2021; 13 Chen (ref_61) 2007; 28 Heubner (ref_12) 2009; 24 Basu (ref_4) 2021; 230 ref_6 |
| References_xml | – volume: 27 start-page: 363 year: 2018 ident: ref_87 article-title: Tumor necrosis factor-α (TNF-α) − 308 G/A and lymphotoxin-α (LT-α) +252 A/G genetic polymorphisms in Egyptian acute lymphoblastic leukemia publication-title: Comp. Clin. Pathol. doi: 10.1007/s00580-017-2600-6 – ident: ref_36 doi: 10.1371/journal.pone.0085187 – volume: 44 start-page: 517 year: 2011 ident: ref_7 article-title: A Unified Model of Mammalian BCL-2 Protein Family Interactions at the Mitochondria publication-title: Mol. Cell doi: 10.1016/j.molcel.2011.10.001 – volume: 33 start-page: e22961 year: 2019 ident: ref_88 article-title: Chronic myeloid leukemia blast crisis presented with AML of t(9;22) and t(3;14) mimicking acute lymphocytic leukemia publication-title: J. Clin. Lab. Anal. doi: 10.1002/jcla.22961 – volume: 42 start-page: 3799 year: 2022 ident: ref_71 article-title: The Contribution of Interleukin-8 Rs4073 Genotypes to Triple Negative Breast Cancer Risk in Taiwan publication-title: Anticancer Res. doi: 10.21873/anticanres.15870 – volume: 41 start-page: 185 year: 2019 ident: ref_69 article-title: Role and regulation of pro-apoptotic Bax in oral squamous cell carcinoma and drug resistance publication-title: Head Neck-J. Sci. Spec. Head Neck doi: 10.1002/hed.25471 – volume: 34 start-page: 166 year: 2010 ident: ref_15 article-title: BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients publication-title: Leuk. Res. doi: 10.1016/j.leukres.2009.05.009 – volume: 2014 start-page: 149185 year: 2014 ident: ref_32 article-title: Chronic Inflammation and Cytokines in the Tumor Microenvironment publication-title: J. Immunol. Res. doi: 10.1155/2014/149185 – volume: 69 start-page: 338 year: 2009 ident: ref_80 article-title: Low Levels of Tumor Necrosis Factor α Increase Tumor Growth by Inducing an Endothelial Phenotype of Monocytes Recruited to the Tumor Site publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-08-1565 – volume: 12 start-page: 2833 year: 2021 ident: ref_89 article-title: Clonal evolution and clinical implications of genetic abnormalities in blastic transfor-mation of chronic myeloid leukaemia publication-title: Nat. Commun. doi: 10.1038/s41467-021-23097-w – volume: 71 start-page: 5296 year: 2011 ident: ref_76 article-title: IL-8 signaling plays a critical role in the epitheli-al-mesenchymal transition of human carcinoma cells publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-11-0156 – volume: 41 start-page: 1 year: 2004 ident: ref_49 article-title: The chronic myeloproliferative disorders: Clonality and clinical heterogeneity publication-title: Semin. Hematol. doi: 10.1053/j.seminhematol.2004.02.011 – volume: 113 start-page: 2517 year: 2009 ident: ref_53 article-title: Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia publication-title: Blood doi: 10.1182/blood-2008-07-169110 – volume: 2 start-page: 647 year: 2002 ident: ref_5 article-title: The Bcl2 family: Regulators of the cellular life-or-death switch publication-title: Nat. Rev. Cancer doi: 10.1038/nrc883 – volume: 385 start-page: 637 year: 1997 ident: ref_66 article-title: Bax suppresses tumorigenesis and stimulates apoptosis in vivo publication-title: Nature doi: 10.1038/385637a0 – volume: 5 start-page: 18411 year: 2015 ident: ref_38 article-title: IL-8 as mediator in the microenvironment-leukaemia network in acute myeloid leukaemia publication-title: Sci. Rep. doi: 10.1038/srep18411 – volume: 24 start-page: 223 year: 2009 ident: ref_12 article-title: Association of the AA genotype of the Bcl-2 (-938C > A) promoter polymorphism with better survival in ovarian cancer publication-title: Int. J. Biol. Markers doi: 10.1177/172460080902400402 – ident: ref_40 doi: 10.3390/cancers12020524 – volume: 6 start-page: 183 year: 2011 ident: ref_51 article-title: Polymorphisms in the Apoptotic Pathway Gene BCL-2 and Survival in Small Cell Lung Cancer publication-title: J. Thorac. Oncol. doi: 10.1097/JTO.0b013e3181f8a20e – volume: 59 start-page: 475 year: 2012 ident: ref_63 article-title: The clinicopathological significance of Bax and Bcl-2 protein expression with tumor infiltrating lymphocytes in ovarian carcinoma publication-title: Neoplasma doi: 10.4149/neo_2012_061 – volume: 40 start-page: 570 year: 2012 ident: ref_64 article-title: The effect of raloxifene on Bax protein expression in breast carcinomas of postmenopausal women publication-title: Diagn. Cytopathol. doi: 10.1002/dc.21580 – volume: 13 start-page: 369 year: 2019 ident: ref_83 article-title: TGF-β1 and TNF-α synergistically induce epithelial to mesenchymal transition of breast cancer cells by enhancing TAK1 activation publication-title: J. Cell Commun. Signal. doi: 10.1007/s12079-019-00508-8 – volume: 9 start-page: 15286 year: 2019 ident: ref_41 article-title: Genomic Prediction of 16 Complex Disease Risks Including Heart Attack, Diabetes, Breast and Prostate Cancer publication-title: Sci. Rep. doi: 10.1038/s41598-019-51258-x – volume: 186 start-page: 378 year: 1998 ident: ref_67 article-title: Infrequent bax gene mutations in B-cell lymphomas publication-title: J. Pathol. doi: 10.1002/(SICI)1096-9896(199812)186:4<378::AID-PATH203>3.0.CO;2-5 – volume: 68 start-page: 394 year: 2018 ident: ref_1 article-title: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21492 – volume: 84 start-page: 214 year: 2013 ident: ref_17 article-title: Effect of the BCL2 Gene Polymorphism on Survival in Advanced-Stage Non-Small Cell Lung Cancer Patients Who Received Chemotherapy publication-title: Oncology doi: 10.1159/000342854 – volume: 230 start-page: 107943 year: 2021 ident: ref_4 article-title: The interplay between apoptosis and cellular senescence: Bcl-2 family proteins as targets for cancer therapy publication-title: Pharmacol. Ther. doi: 10.1016/j.pharmthera.2021.107943 – ident: ref_85 doi: 10.3390/genes13071237 – volume: 407 start-page: 770 year: 2000 ident: ref_9 article-title: The biochemistry of apoptosis publication-title: Nature doi: 10.1038/35037710 – volume: 72 start-page: 3666 year: 1975 ident: ref_78 article-title: An endotoxin-induced serum factor that causes necrosis of tumors publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.72.9.3666 – ident: ref_46 doi: 10.3390/ijms21041177 – ident: ref_77 doi: 10.3390/cancers13030529 – volume: 8 start-page: 935 year: 2018 ident: ref_81 article-title: Immunotherapy Resistance by Inflammation-Induced Dedifferentiation publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-17-1178 – volume: 82 start-page: 2517 year: 1993 ident: ref_39 article-title: Constitutive Expression of Interleukin-8 and its Re-ceptor in Human Myeloid and Lymphoid Leukemia publication-title: Blood doi: 10.1182/blood.V82.8.2517.2517 – volume: 72 start-page: 1290 year: 2012 ident: ref_82 article-title: Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-11-3123 – volume: 123 start-page: 562 year: 2005 ident: ref_56 article-title: Role of bax Mutations in Apoptosis in Colorectal Cancers With Microsatellite Instability publication-title: Am. J. Clin. Pathol. doi: 10.1309/JQ2X3RV3L8F9TGYW – volume: 121 start-page: 934 year: 2019 ident: ref_31 article-title: Hsp60 and IL-8 axis promotes apoptosis resistance in cancer publication-title: Br. J. Cancer doi: 10.1038/s41416-019-0617-0 – ident: ref_48 doi: 10.1002/9781444318531 – volume: 21 start-page: 479 year: 1997 ident: ref_10 article-title: Bcl-2 and c-myc expression, cell cycle kinetics and apoptosis during the progression of chronic myelogenous leukemia from diagnosis to blastic phase publication-title: Leuk. Res. doi: 10.1016/S0145-2126(97)00006-4 – volume: 38 start-page: 661 year: 2008 ident: ref_60 article-title: Low Expression of Bax Predicts Poor Prognosis in Resected Non-small Cell Lung Cancer Patients with Non-squamous Histology publication-title: Jpn. J. Clin. Oncol. doi: 10.1093/jjco/hyn089 – volume: 13 start-page: 4146 year: 2007 ident: ref_57 article-title: Low Expression of Bax Predicts Poor Prognosis in Patients with Locally Advanced Esophageal Cancer Treated with Definitive Chemoradiotherapy publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-06-3063 – volume: 28 start-page: 2008 year: 2007 ident: ref_61 article-title: Single-nucleotide poly-morphisms at the TP53-binding or responsive promoter regions of Bax and Bcl-2 genes and risk of squamous cell carcinoma of the head and neck publication-title: Carcinogenesis doi: 10.1093/carcin/bgm172 – volume: 45 start-page: 17 year: 2017 ident: ref_35 article-title: Tumor necrosis factor α in the onset and progression of leukemia publication-title: Exp. Hematol. doi: 10.1016/j.exphem.2016.10.005 – volume: 58 start-page: 1807 year: 2009 ident: ref_28 article-title: Proinflammatory cytokines activate the intrinsic apoptotic pathway in beta-cells publication-title: Diabetes doi: 10.2337/db08-0178 – volume: 14 start-page: e24835 year: 2022 ident: ref_84 article-title: Serum Tumor Necrosis Factor-Alpha Levels in Acute Leukemia and Its Prognostic Significance publication-title: Cureus – volume: 36 start-page: 355 year: 2009 ident: ref_3 article-title: Emerging Role for Members of the Bcl-2 Family in Mitochondrial Morphogenesis publication-title: Mol. Cell doi: 10.1016/j.molcel.2009.10.011 – volume: 129 start-page: 2390 year: 2011 ident: ref_52 article-title: Regulatory BCL2 promoter polymorphism (−938C>A) is associated with adverse outcome in patients with prostate carcinoma publication-title: Int. J. Cancer doi: 10.1002/ijc.25904 – ident: ref_47 doi: 10.3390/ijms222212516 – ident: ref_22 doi: 10.1371/journal.pone.0060915 – volume: 114 start-page: 1631 year: 2011 ident: ref_16 article-title: Association of the CC genotype of the regulatory BCL2 promoter polymorphism (−938C>A) with better 2-year survival in patients with glioblastoma multiforme publication-title: J. Neurosurg. doi: 10.3171/2010.12.JNS10478 – volume: 8 start-page: 2050312120965752 year: 2020 ident: ref_33 article-title: Inflammatory cytokines in the pathogenesis of cardiovascular disease and cancer publication-title: SAGE Open Med. doi: 10.1177/2050312120965752 – volume: 17 start-page: 1364 year: 1999 ident: ref_55 article-title: Analysis of the p53/Bax pathway in colorectal cancer: Low Bax is a negative prognostic factor in patients with resected liver metastases publication-title: J. Clin. Oncol. doi: 10.1200/JCO.1999.17.5.1364 – ident: ref_19 doi: 10.1371/journal.pone.0077534 – volume: 18 start-page: 121 year: 2019 ident: ref_26 article-title: Inflammation and cancer publication-title: Ann. Afr. Med. doi: 10.4103/aam.aam_56_18 – volume: 20 start-page: 599 year: 2006 ident: ref_59 article-title: Apoptotic markers p53, Bcl-2 and Bax in primary lung cancer publication-title: Vivo – volume: 216 start-page: 1474 year: 2019 ident: ref_29 article-title: Cell death–mediated cytokine release and its therapeutic implications publication-title: J. Exp. Med. doi: 10.1084/jem.20181892 – volume: 1 start-page: 11 year: 2008 ident: ref_50 article-title: Analysis of single nucleotide polymorphisms in the FAS and CTLA-4 genes of pe-ripheral T-cell lymphomas publication-title: J. Hematop. doi: 10.1007/s12308-008-0003-y – ident: ref_44 doi: 10.1007/978-3-642-16483-5 – volume: 9 start-page: 381 year: 2012 ident: ref_62 article-title: Expression of Bcl-2 and Bax in Advanced or Metastatic Prostate Carcinoma publication-title: Urol. J. – volume: 270 start-page: 96 year: 1995 ident: ref_65 article-title: Bax-Deficient Mice with Lymphoid Hyperplasia and Male Germ Cell Death publication-title: Science doi: 10.1126/science.270.5233.96 – volume: 10 start-page: 424 year: 2017 ident: ref_42 article-title: Polymorphisms of BCL2 Gene in Acute Lymphoblastic Leukemia Patients in Pa-kistan and Screening of Phytochemicals to Overcome its Expression publication-title: Biol. Med. doi: 10.4172/0974-8369.1000424 – ident: ref_14 doi: 10.1186/1471-2407-13-452 – volume: 37 start-page: 5 year: 2023 ident: ref_45 article-title: Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia publication-title: Leukemia doi: 10.1038/s41375-022-01736-5 – volume: 30 start-page: 3667 year: 2011 ident: ref_8 article-title: Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases publication-title: EMBO J. doi: 10.1038/emboj.2011.307 – volume: 65 start-page: 829 year: 2022 ident: ref_30 article-title: Proinflammatory cytokines induce rapid, NO-independent apoptosis, ex-pression of chemotactic mediators and interleukin-32 secretion in human pluripotent stem cell-derived beta cells publication-title: Diabetologia doi: 10.1007/s00125-022-05654-0 – volume: 10 start-page: 1818 year: 2019 ident: ref_34 article-title: The TNF Paradox in Cancer Progression and Im-munotherapy publication-title: Front. Immunol. doi: 10.3389/fimmu.2019.01818 – volume: 23 start-page: 1514 year: 2005 ident: ref_24 article-title: Common Polymorphism G(-248)A in the Promoter Region of the bax Gene Results in Significantly Shorter Survival in Patients With Chronic Lymphocytic Leukemia Once Treatment Is Initiated publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2005.02.192 – volume: 48 start-page: 0300060520904863 year: 2020 ident: ref_72 article-title: Association of interleukin 10 rs1800896 polymorphism with susceptibility to breast cancer: A meta-analysis publication-title: J. Int. Med. Res. doi: 10.1177/0300060520904863 – volume: 198 start-page: 83 year: 2004 ident: ref_21 article-title: Prognostic significance of p53, Bcl-2, and Bax expression in early breast cancer publication-title: J. Am. Coll. Surg. doi: 10.1016/j.jamcollsurg.2003.08.008 – volume: 16 start-page: 7097 year: 2018 ident: ref_58 article-title: Correlation between Bax gene polymorphisms and esophagus cancer publication-title: Oncol. Lett. – volume: 15 start-page: 210 year: 2013 ident: ref_74 article-title: Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells publication-title: Breast Cancer Res. BCR doi: 10.1186/bcr3436 – volume: 8 start-page: 5492 year: 2019 ident: ref_86 article-title: Cytokine rs361525, rs1800750, rs1800629, rs1800896, rs1800872, rs1800795, rs1800470, and rs2430561 SNPs in relation with prognostic factors in acute myeloid leukemia publication-title: Cancer Med. doi: 10.1002/cam4.2424 – ident: ref_25 doi: 10.1186/1471-2350-12-48 – ident: ref_27 doi: 10.3390/cells10010100 – volume: 74 start-page: 845 year: 1993 ident: ref_79 article-title: A novel domain within the 55 kd TNF receptor signals cell death publication-title: Cell doi: 10.1016/0092-8674(93)90464-2 – ident: ref_6 – volume: 106 start-page: 346 year: 2002 ident: ref_54 article-title: Bax-Induction Gene Therapy of Pancreatic Cancer publication-title: J. Surg. Res. doi: 10.1006/jsre.2002.6473 – volume: 13 start-page: 225 year: 2021 ident: ref_37 article-title: Interleukin 8 Elicits Rapid Physiological Changes in Neutrophils That Are Altered by Inflammatory Conditions publication-title: J. Innate Immun. doi: 10.1159/000514885 – ident: ref_2 – volume: 182 start-page: 721 year: 2009 ident: ref_13 article-title: The bcl2 −938CC Genotype Has Poor Prognosis and Lower Survival in Renal Cancer publication-title: J. Urol. doi: 10.1016/j.juro.2009.03.081 – ident: ref_90 doi: 10.3390/jpm12101607 – volume: 35 start-page: 2259 year: 2014 ident: ref_23 article-title: Association of BCL2-938C>A genetic polymorphism with glioma risk in Chinese Han population publication-title: Tumor Biol. doi: 10.1007/s13277-013-1299-5 – volume: 88 start-page: 136 year: 1996 ident: ref_18 article-title: The Bax gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas publication-title: Cancer Genet. Cytogenet. doi: 10.1016/0165-4608(95)00341-X – volume: 57 start-page: 91 year: 2020 ident: ref_75 article-title: Association of il-8 -251t>a (rs4073) polymorphism with susceptibility to gastric cancer: A systematic review and meta-analysis based on 33 case-control studies publication-title: Arq. Gastroenterol. doi: 10.1590/s0004-2803.202000000-16 – volume: 97 start-page: 8 year: 2018 ident: ref_70 article-title: Prognostic value and susceptibility of Bax rs4645878 polymorphism in cancer A systematic review and meta-analysis publication-title: Medicine doi: 10.1097/MD.0000000000011591 – volume: 13 start-page: 5790 year: 2007 ident: ref_11 article-title: The AA Genotype of the Regulatory BCL2 Promoter Polymorphism (−938C>A) Is Associated with a Favorable Outcome in Lymph Node–Negative Invasive Breast Cancer Patients publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-06-2673 – volume: 15 start-page: 809 year: 2022 ident: ref_73 article-title: IL-10 rs1800896 Polymorphism: A Risk Factor for Adult Acute Lymphoblastic Leukemia publication-title: Pharm. Pers. Med. – volume: 51 start-page: 196 year: 2006 ident: ref_43 article-title: Association of IL8, CXCR2 and TNF-alpha polymorphisms and airway disease publication-title: J. Hum. Genet. doi: 10.1007/s10038-005-0344-7 – volume: 23 start-page: 335 year: 2021 ident: ref_68 article-title: Homeostasis: Apoptosis and cell cycle in normal and pathological prostate publication-title: Aging Male doi: 10.1080/13685538.2018.1470233 – volume: 436 start-page: 224 year: 2000 ident: ref_20 article-title: Protein expression of p53, p21 (WAF1/CIP1), Bcl-2, Bax, cyclin D1 and pRb in human colon carcinomas publication-title: Virchows Arch.-Int. J. Pathol. doi: 10.1007/s004280050034 |
| SSID | ssj0057871 ssib044733985 |
| Score | 2.3592408 |
| Snippet | The regulation of apoptosis (the programmed cell death) is dependent on the crucial involvement of BCL2 and BAX. The Bax-248G>A and Bcl-2-938 C>A polymorphic... The regulation of apoptosis (the programmed cell death) is dependent on the crucial involvement of BCL2 and BAX. The and polymorphic variations in the promoter... The regulation of apoptosis (the programmed cell death) is dependent on the crucial involvement of BCL2 and BAX. The Bax-248G>A and Bcl-2-938 C>A polymorphic... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 3933 |
| SubjectTerms | apoptosis CML—chronic myeloid leukaemia gene promoter MPDs proinflammatory cytokines single nucleotide polymorphisms |
| Title | Molecular Evaluation of the Impact of Polymorphic Variants in Apoptotic (Bcl-2/Bax) and Proinflammatory Cytokine (TNF-α/IL-8) Genes on the Susceptibility and Progression of Myeloproliferative Neoplasms: A Case-Control Biomarker Study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/37232720 https://www.proquest.com/docview/2820015879 https://pubmed.ncbi.nlm.nih.gov/PMC10217376 https://doaj.org/article/4b2084de906d4f3ab8d23371b91824bc |
| Volume | 45 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LjtMwFLXQSEhsEG_CY2QkkGaEoiaxG9vs2qrVDKLVSMyg2UWO7UBFm1R9SHTDP_EjfAhfwb12W1oEYsMmysOxnfg4Pjc-vpeQlzJ3jmuhYq1SGXPedrGyqCI0OIuWwy7HxcnDUX52xd9et6_3Qn2hJiy4Bw4vrsXLLJHcOpXAjRXTpbQZYyItIe-Mlwa_volK9owpQBLngjH1iwgjLNOwzgi6VMJEkMBDmqRlxtOSAw9Asn0wOHkf_n8inr_rJ_cGpMEdcnvDJGknPMFdcsPV98jNEFtyfZ_8GG4D39L-zqM3bSoKjI-e-7WReHTRTMD6h5c9NvQD2M0oi6HjmnZmzWzZQNb0pGsmcdbq6i-nVNeWXswbQCUAaeon6GlvvWw-A1elJ5ejQfz9W-v8XSxPKfqzXlAoEst7v1p4-YxX4q632XwMGlxfq-EatUsYQqhywRk5HaG4XS-mize0Q3sw2sa9oKun8JBTlBXNKcog1w_I1aB_2TuLN4EdYsPb6TIWXEvNFU8rYJfOOsuVBR5nE1dyZZKq4twCL4KvgzIa-GYlZOUcy1zlctluG_aQHNVN7R4TyhjPtLBpYrSGm6yGXl9JV1qdG6dZGpHX2xYtzMbrOQbfmBRg_WD7F_vtH5FXu9Sz4O3jL-m6CI5dGvTR7U8AcosNcot_ITciL7bQKqBP40SNrl2zWhRgBiOXlUJF5FGA2q4oJoADiyyJiDwA4UFdDq_U40_ebzhGcRcwoDz5H7V_Sm5lwPe89jN7Ro6W85V7DvxsWR77rgjb4df-sf999hP9Zjyx |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Molecular+Evaluation+of+the+Impact+of+Polymorphic+Variants+in+Apoptotic+%28+Bcl-2%2FBax+%29+and+Proinflammatory+Cytokine+%28+TNF-%CE%B1%2FIL-8+%29+Genes+on+the+Susceptibility+and+Progression+of+Myeloproliferative+Neoplasms%3A+A+Case-Control+Biomarker+Study&rft.jtitle=Current+issues+in+molecular+biology&rft.au=Moawadh%2C+Mamdoh+S&rft.au=Mir%2C+Rashid&rft.au=Tayeb%2C+Faris+J&rft.au=Asim%2C+Orooba&rft.date=2023-05-02&rft.eissn=1467-3045&rft.volume=45&rft.issue=5&rft.spage=3933&rft_id=info:doi/10.3390%2Fcimb45050251&rft_id=info%3Apmid%2F37232720&rft.externalDocID=37232720 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1467-3045&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1467-3045&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1467-3045&client=summon |